Online first
Review paper
Published online: 2024-04-30

open access

Page views 74
Article views/downloads 49
Get Citation

Connect on Social Media

Connect on Social Media

Guidelines are one thing, practice is another. With newer and newer guidelines, why can’t we manage to control modifiable cardiovascular risk factors?

Małgorzata Wierzowiecka1, Marek Zieliński12, Andrzej Tykarski1, Arkadiusz Andrzej Niklas1


Summarizing WOBASZ studies, hypertension prevalence increased with age and gender adjustments. Despite a minor drop in awareness, treatment and control rates improved from past studies but remain inadequate. This underscores the urgent need for better awareness and treatment strategies to address hypertension effectively. The data on hyperlipidemia are very alarming. There is a critical need for more effective dyslipidemia prevention and treatment strategies. Over a decade, the WOBASZ Studies observed a 27% surge in diabetes prevalence. Additionally, there was a notable 50% increase in individuals with impaired fasting glucose. The prevalence of obesity has increased significantly in Poland over the last decade, particularly in men. It is concerning that every fourth inhabitant of Poland is now obese. Abdominal obesity is observed in every third man and nearly every second woman, with an excess of abdominal fat increasing in both sexes. Physical activity is another topic that requires significantly more attention as it is really insufficient among Polish population. Poland, regrettably, continues to be among the countries where the issue of smoking remains very much present, carrying with it not only health consequences but also socioeconomic implications. Data from WOBASZ studies indicate a significant gap between the perceived and actual nutritional adequacy among Polish individuals, underscoring the critical need for improved dietary practices. Addressing CVD prevention is a critical objective at both personal and societal levels, necessitating active engagement from healthcare professionals and policymakers. We propose a change, potentially somewhat controversial, in the approach to prevention and treatment.

Article available in PDF format

View PDF Download PDF file


  1. Statystyka zgonów i umieralności z powodu chorób układu krążenia.
  2. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224–2260.
  3. Visseren FLJ, Mach F, Smulders YM, et al. ESC National Cardiac Societies, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34): 3227–3337.
  4. Kotseva K. EUROASPIRE Investigators. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. Cardiovasc Diagn Ther. 2017; 7(6): 633–639.
  5. Drygas W, Niklas AA, Piwońska A, et al. Multi-centre National Population Health Examination Survey (WOBASZ II study): assumptions, methods, and implementation. Kardiol Pol. 2016; 74(7): 681–690.
  6. Błędowski P, Grodzicki T, Mossakowska M et al. PolSenior 2— Badanie Poszczególnych Obszarów Stanu Zdrowia Osób Starszych, w Tym Jakości Życia Związanej Ze Zdrowiem; 2021.
  7. Kopcia G, Jankowski P, Pająk A, Drygas W. Epidemiology and prevention of cardiovascular diseases. Medycyna Praktyczna, Krakow 2015.
  8. Central Statistical Office. Demographic Yearbook of Poland. Warszawa, 2016 .
  9. Yang Q, Cogswell ME, Flanders WD, et al. Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. JAMA. 2012; 307(12): 1273–1283.
  10. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859): 2224–2260.
  11. Go AS, Mozaffarian D, Roger VL, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014; 129(3): 399–410.
  12. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335(8692): 765–774.
  13. Farley TA, Dalal MA, Mostashari F, et al. Deaths preventable in the U.S. by improvements in use of clinical preventive services. Am J Prev Med. 2010; 38(6): 600–609.
  14. Niklas A, Flotyńska A, Puch-Walczak A, et al. WOBASZ II investigators. Prevalence, awareness, treatment and control of hypertension in the adult Polish population - Multi-center National Population Health Examination Surveys - WOBASZ studies. Arch Med Sci. 2018; 14(5): 951–961.
  15. Niklas AA, Flotyńska A, Zdrojewski T, et al. Trends in hypertension prevalence, awareness, treatment, and control among Polish adults 75 years and older during 2007-2014. Cardiol J. 2018; 25(3): 333–344.
  16. Zdrojewski T, Wizner B, Więcek A, et al. Prevalence, awareness, and control of hypertension in elderly and very elderly in Poland: results of a cross-sectional representative survey. J Hypertens. 2016; 34(3): 532–8; discussion 538.
  17. Joffres M, Falaschetti E, Gillespie C, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013; 3(8): e003423.
  18. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018; 71(19): e127–e248.
  19. Bakris G, Sorrentino M. Redefining Hypertension - Assessing the New Blood-Pressure Guidelines. N Engl J Med. 2018; 378(6): 497–499.
  20. Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people. Lancet. 2014; 383(9932): 1899–1911.
  21. Shen Li, Ma H, Xiang MX, et al. Meta-analysis of cohort studies of baseline prehypertension and risk of coronary heart disease. Am J Cardiol. 2013; 112(2): 266–271.
  22. Verdecchia P, Angeli F, Gentile G, et al. More Versus Less Intensive Blood Pressure-Lowering Strategy: Cumulative Evidence and Trial Sequential Analysis. Hypertension. 2016; 68(3): 642–653.
  23. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373(22): 2103–2116.
  24. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387(10017): 435–443.
  25. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens. 2016; 34(4): 613–622.
  26. Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017 ACC/AHA High Blood Pressure Guideline. Circulation. 2018; 137(2): 109–118.
  27. National Heart, Blood and Lung Institute. National Cholesterol Education Program.
  28. Pająk A, Szafraniec K, Polak M, et al. WOBASZ Investigators. Changes in the prevalence, treatment, and control of hypercholesterolemia and other dyslipidemias over 10 years in Poland: the WOBASZ study. Pol Arch Med Wewn. 2016; 126(9): 642–652.
  29. Jackson R, Lawes CMM, Bennett DA, et al. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual's absolute cardiovascular risk. Lancet. 2005; 365(9457): 434–441.
  30. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003; 289(19): 2534–2544.
  31. Sever P, Dahlöf B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361(9364): 1149–1158.
  32. Niklas A, Marcinkowska J, Kozela M, et al. Blood pressure and cholesterol control in patients with hypertension and hypercholesterolemia: the results from the Polish multicenter national health survey WOBASZ II. Pol Arch Intern Med. 2019; 129(12): 864–873.
  33. Cherry SB, Benner JS, Hussein MA, et al. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health. 2009; 12(4): 489–497.
  34. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE Study Group. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil. 2010; 17(5): 530–540.
  35. Banegas JR, López-García E, Dallongeville J, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J. 2011; 32(17): 2143–2152.
  36. Corrao G, Scotti L, Zambon A, et al. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis. 2011; 217(2): 479–485.
  37. van Gils PF, Over EAB, Hamberg-van Reenen HH, et al. The polypill in the primary prevention of cardiovascular disease: cost-effectiveness in the Dutch population. BMJ Open. 2011; 1(2): e000363.
  38. IDF Diabetes Atlas.
  39. Rutkowski M, Wojciechowska A, Śmigielski W, et al. Prevalence of diabetes and impaired fasting glucose in Poland in 2005-2014: results of the WOBASZ surveys. Diabet Med. 2020; 37(9): 1528–1535.
  40. Clinical recommendations for the management of people with diabetes 2023 Statement of the Polish Diabetes Association. Curr Top Diab. 2023; 3: 1–147.
  41. Rutkowski M, Bandosz P, Czupryniak L, et al. Prevalence of diabetes and impaired fasting glucose in Poland--the NATPOL 2011 Study. Diabet Med. 2014; 31(12): 1568–1571.
  42. NCD Risk Factor Collaboration (NCD-RisC). Global variation in diabetes diagnosis and prevalence based on fasting glucose and hemoglobin A1c. Nat Med. 2023; 29(11): 2885–2901.
  43. Topor-Madry R, Wojtyniak B, Strojek K, et al. Prevalence of diabetes in Poland: a combined analysis of national databases. Diabet Med. 2019; 36(10): 1209–1216.
  44. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384(9945): 766–781.
  45. Müller-Riemenschneider F, Reinhold T, Berghöfer A, et al. Health-economic burden of obesity in Europe. Eur J Epidemiol. 2008; 23(8): 499–509.
  46. Gajewska M, Gorynski P, Wysocki MJ. Hospitalisation of people with obesity in Poland in years 1985-2007. Scand J Public Health. 2011; 39(5): 540–546.
  47. Flegal KM, Kit BK, Orpana H, et al. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013; 309(1): 71–82.
  48. Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014; 56(4): 369–381.
  49. Stepaniak U, Micek A, Waśkiewicz A, et al. Prevalence of general and abdominal obesity and overweight among adults in Poland. Results of the WOBASZ II study (2013-2014) and comparison with the WOBASZ study (2003-2005). Pol Arch Med Wewn. 2016; 126(9): 662–671.
  50. Polakowska M, Piotrowski W, Tykarski A, et al. Tobacco smoking In Polish population. Results from the WOBASZ Project. Pol Popul Rev. 2005; 27: 64–69.
  51. U.S. Department of Health and Human Services. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking‑Attributable Disease: A Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2010.
  52. U.S. Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health 2014.
  53. World Health Organization. WHO global report: mortality attributable to tobacco. World Health Organization, Geneva 2012.
  54. Niewada M, Filipiak K. An Analysis of Health Costs: The economic consequences of nicotine addiction. Pol Przegl Kardiol. 2000; 2: 367–371.
  55. Polakowska M, Kaleta D, Piotrowski W, et al. Tobacco smoking in Poland in the years from 2003 to 2014. Multi‑centre National Population Health Examination Survey (WOBASZ). Pol Arch Intern Med. 2017; 127(2): 91–99.
  56. World Health Organization. Global status report on noncommunicable diseases. World Health Organization, Geneva 2010.
  57. Arem H, Moore SC, Patel A, et al. Leisure time physical activity and mortality: a detailed pooled analysis of the dose-response relationship. JAMA Intern Med. 2015; 175(6): 959–967.
  58. Lee IM, Shiroma EJ, Lobelo F, et al. Lancet Physical Activity Series Working Group. Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy. Lancet. 2012; 380(9838): 219–229.
  59. Kwaśniewska M, Jegier A, Kostka T, et al. Long-term effect of different physical activity levels on subclinical atherosclerosis in middle-aged men: a 25-year prospective study. PLoS One. 2014; 9(1): e85209.
  60. Hallal PC, Andersen LBo, Bull FC, et al. Lancet Physical Activity Series Working Group. Global physical activity levels: surveillance progress, pitfalls, and prospects. Lancet. 2012; 380(9838): 247–257.
  61. Bandosz P, O'Flaherty M, Drygas W, et al. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ. 2012; 344: d8136.
  62. Kwaśniewska M, Pikala M, Bielecki W, et al. Ten-Year Changes in the Prevalence and Socio-Demographic Determinants of Physical Activity among Polish Adults Aged 20 to 74 Years. Results of the National Multicenter Health Surveys WOBASZ (2003-2005) and WOBASZ II (2013-2014). PLoS One. 2016; 11(6): e0156766.
  63. Zhan J, Liu YJ, Cai LB, et al. Fruit and vegetable consumption and risk of cardiovascular disease: A meta-analysis of prospective cohort studies. Crit Rev Food Sci Nutr. 2017; 57(8): 1650–1663.
  64. Gil Á, Martinez de Victoria E, Olza J. Indicators for the evaluation of diet quality. Nutr Hosp. 2015; 31 Suppl 3: 128–144.
  65. Stamler J. Diet-heart: a problematic revisit. Am J Clin Nutr. 2010; 91(3): 497–499.
  66. Szostak-Wegierek D, Kłosiewicz-Latoszek L, Szostak WB, et al. The role of dietary fats for preventing cardiovascular disease. A review. Rocz Panstw Zakl Hig. 2013; 64(4): 263–269.
  67. Siri-Tarino PW, Sun Qi, Hu FB, et al. Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr. 2010; 91(3): 502–509.
  68. Waśkiewicz A, Szcześniewska D, Szostak-Węgierek D, et al. Are dietary habits of the Polish population consistent with the recommendations for prevention of cardiovascular disease? - WOBASZ II project. Kardiol Pol. 2016; 74(9): 969–977.
  69. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438): 937–952.
  70. Piwońska A, Piotrowski W, Kozela M, et al. Cardiovascular diseases prevention in Poland: results of WOBASZ and WOBASZ II studies. Kardiol Pol. 2018; 76(11): 1534–1541.
  71. World Health Organization. Innovative Care for Chronic Conditions: Building Blocks for Action. World Health Organization, Geneva 2002.